Remember Retina UK in your Will
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Search
Search results
‘Talking’ Travel Peer Support Group
Tuesday 10 December 2024, 7.00pm - 8.00pm - via Zoom - Come and join Richard & Rachael to hear from our guest speaker, Anthony Gough, Trustee at North Wales Accessible Holidays for Blind and Visually Impaired.
‘Talking’ Tech Peer Support Group
Thursday 7 November 2024, 7.00pm - 8.00pm - via Zoom - Join us for a tech round up following on from our visit to the London Sight Village event.
Retina UK Annual Conference 2024
The Retina UK Annual Conference will be held on Saturday 28 September. You can join the Conference in-person or online.
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
BBC investigates unproven treatments for retinitis pigmentosa
The BBC World Service has undertaken an investigation of unproven treatments for retinitis pigmentosa (RP) and has produced a documentary film, called Blind Faith, which is available on BBC iPlayer.
Antabuse moves into clinical trial for people with RP
Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.
Giving in memory
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
How we can work together
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.